A case-control study correlated enhanced resistin plasmatic levels to IR and CRC risk [105], while a clinical study on prediabetic subjects assessed the protective role of adiponectin against CRC by regulating TNF-α and VEGF levels [106]. The gene discussed is ADIPOQ; the disease is colorectal carcinoma.